pdufa.bio
CalendarDecisionsApprovals/yrTrial oddsLearnResearchMethodology
Home › PDUFA Calendar › PFE

PFE PDUFA Date: TUKYSA, trastuzumab, and pertuzumab

FDA decision (PDUFA) target 2026-12-31 · Pfizer Inc. · HER2+ Metastatic Breast Cancer

PFE run-up into the PDUFA (last ~120 days)

$28.55$25.33
Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA PDUFA target date2026-12-31
Drug / candidateTUKYSA, trastuzumab, and pertuzumab
IndicationHER2+ Metastatic Breast Cancer
CompanyPfizer Inc.
Market-cap tierLarge
Cohort decision-day move (history)±1% median
ClinicalTrials.gov—

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

Track this live → price, options (expected move & IV) and the full dashboard
Opens the pdufa.bio app (private beta)

FAQ

When is the PFE PDUFA date?
The FDA PDUFA target date for PFE (Pfizer Inc.) is 2026-12-31 for TUKYSA, trastuzumab, and pertuzumab. Dates are company/FDA-sourced and can slip — verify against primary filings.
What is PFE's drug TUKYSA, trastuzumab, and pertuzumab?
TUKYSA, trastuzumab, and pertuzumab is Pfizer Inc.'s candidate under FDA review for HER2+ Metastatic Breast Cancer.
What typically happens to a large-cap stock into a PDUFA date?
Historically, large-cap names had a median decision-day move around ±1% (694-PDUFA cohort, 2024–26). This is historical context by market-cap tier, not a prediction for this drug.